Epigenetics Drugs & Diagnostic Technologies Market Analysis-2027

Epigenetics Drugs & Diagnostic Technologies Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
SEATTLE - Nov. 20, 2020 - PRLog -- Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions such as cancer, heart disease, diabetes, and mental illnesses. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic use.

Global Epigenetic Drugs and Diagnostic Technologies Market: Drivers

Approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. For instance, in January 2020, the U.S. Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Global Epigenetic Drugs and Diagnostic Technologies Market: Opportunities

Adoption of Artificial Intelligence (AI) for R&D in epigenetic drugs is expected to offer lucrative growth opportunities for players in the global epigenetic drugs and diagnostic technologies market.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/epigenetics-drugs-and-diagnostic-technologies-market-4026

Key Takeaways:

The global epigenetic drugs and diagnostic technologies market was valued at US$ 6,800.3 Mn in 2019 and is forecast to reach a value of US$ 28,606.6 Mn by 2027 at a CAGR of 19.7% between 2020 and 2027. Increasing approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4026

Market Trends

Players in the market are focused on R&D of new drugs to expand their product portfolio. For instance, in July 2020, Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics for R&D of novel therapies, presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020.

Major players in the market are also focused on raising funds for R&D of new technologies. For instance, in June 2020, Base Genomics, an epigenetics company, raised US$ 11 million to progress development of its TAPS technology, a novel chemical reaction that converts methylated cytosine to thymine under mild conditions.

Global Epigenetic Drugs and Diagnostic Technologies Market: Key Developments

June 2020: Epizyme, Inc. received the U.S. Food and Drug Administration's supplemental New Drug Application approval for TAZVERIK (tazemetostat) for the following two distinct follicular lymphoma indications.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4026

Contact
Mr. Shah
sales@coherentmarketinsights.com
+1-206-701-6702
End
Source: » Follow
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share